Boston Scientific commences new Emblem MRI S-ICD study

Boston Scientific has announced the commencement of a new global study assessing the performance of its Emblem MRI subcutaneous implantable defibrillator (S-ICD) system.

The trial will evaluate the survival benefit of patients treated with the Emblem MRI S-ICD who are aged 65 and older with a history of prior heart attack, diabetes and moderately reduced left ventricular ejection fraction.

This subset of patients is at increased risk for sudden cardiac arrest, but not currently considered guideline-appropriate candidates for implantable cardiac defibrillators. Specifically, this trial is part of a pilot initiative to increase the percentage of females enrolled in clinical studies.

With the first patient now enrolled, the trial is intended to determine if the EMBLEM MRI S-ICD system improves survival compared to patients remaining on their current medical therapy.

Dr Kenneth Stein, senior vice-president and chief medical officer for global health policy and rhythm management at Boston Scientific, said: "We are excited for the opportunity to improve the broad applicability of the MADIT S-ICD trial results by increasing the enrolment of women in this study."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.